Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Depression 3Breast Neoplasms 2Anxiety Disorders 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lung Neoplasms 1Hospice 1Hematopoietic and Lymphoid System Neoplasm 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Emotional Regulation 1Colonic Neoplasms 1Advanced Cancer 1Acute Pain 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Psychotherapy × Clear all
NCT07336238 2026-05-29

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

University of Washington

Phase 2 Recruiting
18 enrolled

Anxiety Disorders, Depression, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡